This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why Inhibikase Therapeutics, Inc. (IKT) Is a Great 'Buy the Bottom' Stock Now
by Zacks Equity Research
Inhibikase Therapeutics, Inc. (IKT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
New Strong Buy Stocks for February 13th
by Zacks Equity Research
IKT, ETRN, ADMA, AFRM and ORC have been added to the Zacks Rank #1 (Strong Buy) List on February 13, 2023.
Best Momentum Stocks to Buy for February 8th
by Zacks Equity Research
POST, IKT and ACMR made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on February 8, 2023.
New Strong Buy Stocks for February 8th
by Zacks Equity Research
IKT, POST, ASAN, ACMR and HENKY have been added to the Zacks Rank #1 (Strong Buy) List on February 8, 2023.
Best Momentum Stocks to Buy for January 31st
by Zacks Equity Research
ADMA, EKSO and IKT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 31, 2024.
New Strong Buy Stocks for January 31st
by Zacks Equity Research
ADMA, IKT, YPF, AVXL and EKSO have been added to the Zacks Rank #1 (Strong Buy) List on January 31, 2024.
Best Momentum Stocks to Buy for January 26th
by Zacks Equity Research
PCAR, IKT and PD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 26, 2023.
New Strong Buy Stocks for January 26th
by Zacks Equity Research
IKT, EGO, MDB, PD and AVXL have been added to the Zacks Rank #1 (Strong Buy) List on January 26, 2023.
Inhibikase Therapeutics, Inc. (IKT) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Inhibikase Therapeutics, Inc. (IKT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.